As advised via Pharmac Tender announcement 31 March 2017 there is to be a change in the listing and future sole supply.

New listing from 1 October 2017 – Escitalopram-Apo ┬áin both 10 mg and 20 mg.

The incumbent brand Escitalopram Airflow will be reference priced to Escitalopram-Apo from 1 December 2017.

The subsidy will reduce between 20.71% and 20.83%.

At this time we are not being provided with price support from the supplier.

On that basis we would recommend you continue to purchase the incumbent and we will change automatically no later than 1 December 2017 or as soon as existing stocks are depleted.

Once again we need your support to ensure stock in the supply chain moves through to effectively ensure no losses are incurred.

We thank you in anticipation of your on going support.


About The Author